Managing Risk Factors for Atherosclerosis in Critical Limb Ischaemia

European Journal of Vascular and Endovascular Surgery

Volumn 32, Issue 5, 2006, Pages 478-483

  Gottsater A ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Antiplatelet; Atherosclerosis; Critical limb ischaemia; Hyperlipidemia; Hypertension; Medical treatment; Smoking

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINE; NICOTINE GUM; PIOGLITAZONE; RAMIPRIL; SIMVASTATIN;

BRAIN ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIMB ISCHEMIA; MORTALITY; NICOTINE REPLACEMENT THERAPY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK MANAGEMENT; SMOKING CESSATION; STROKE; TOBACCO DEPENDENCE; TREATMENT PLANNING;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; DIABETES COMPLICATIONS; EXTREMITIES; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPOLIPIDEMIC AGENTS; ISCHEMIA; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SMOKING;

EID: 33749420122     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2006.03.007     Document Type: Review

References (74)

1. Dormandy J.A., and Rutherford R.B. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Concensus (TASC). J Vasc Surg 31 (2000) S1-S296
2. Fowkes F.G. Epidemiology of atherosclerotic arterial disease in the lower limbs. Eur J Vasc Surg 2 (1988) 283-291
3. Mautner G.C., Mautner S.L., and Roberts W.C. Amounts of coronary arterial narrowing by atherosclerotic plaque at necropsy in patients with lower extremity amputation. Am J Cardiol 70 (1992) 1147-1151
4. Aronow W.S., and Ahn C. Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age. Am J Cardiol 74 (1994) 64-65
5. Ness J., and Aronow W.S. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatr Soc 47 (1999) 1255-1256
6. Aronow W.S., Ahn C., and Kronzon I. Association of valvular aortic stenosis with symptomatic peripheral arterial disease in older persons. Am J Cardiol 88 (2001) 1046-1047
7. Hertzer N.R. Fatal myocardial infarction following lower extremity revascularization. Two hundred seventy-three patients followed six to eleven postoperative years. Ann Surg 193 (1981) 492-498
8. Jonsson B., and Skau T. Ankle-brachial index and mortality in a cohort of questionnaire recorded leg pain on walking. Eur J Vasc Endovasc Surg 24 (2002) 405-410 10.1053/ejvs.2002.1747
9. Ostergren J., Sleight P., Dagenais G., Danisa K., Bosch J., Qilong Y., et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 25 (2004) 17-24
10. Criqui M.H., Langer R.D., Fronek A., Feigelson H.S., Klauber M.R., McCann T.J., et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326 (1992) 381-386
11. Vogt M.T., Cauley J.A., Newman A.B., Kuller L.H., and Hulley S.B. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 270 (1993) 465-469
12. Leng G.C., Lee A.J., Fowkes F.G., Whiteman M., Dunbar J., Housley E., et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 25 (1996) 1172-1181
13. Wolfe J. Defining the outcome of critical ischaemia: a one year prospective study. Br J Surg 73 (1986) 321
14. The I.C.A.I. Group (Gruppo di Studio dell'Ischemia Cronica Critica degli Arti Inferiori). The study group of criticial chronic ischemia of the lower exremities. Long-term mortality and its predictors in patients with critical leg ischaemia. Eur J Vasc Endovasc Surg 14 (1997) 91-95
15. Barani J., Nilsson J., Mattiasson I., Lindblad B., and Gottsäter A. Inflammatory mediators are associated with 1-year mortality in critical limb ischemia. J Vasc Surg 42 (2005) 75-80
16. Lassila R., Lepantalo M., and Lindfors O. Peripheral arterial disease-natural outcome. Acta Med Scand 220 (1986) 295-301
17. Balmer H., Mahler F., Do D.D., Triller J., and Baumgartner I. Balloon angioplasty in chronic critical limb ischemia: factors affecting clinical and angiographic outcome. J Endovasc Ther 9 (2002) 403-410
18. Mangano D.T. Perioperative cardiac morbidity. Anesthesiology 72 (1990) 153-184
19. Adler A.I., Stevens R.J., Neil A., Stratton I.M., Boulton A.J., and Holman R.R. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 25 (2002) 894-899
20. Kannel W.B. Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk 1 (1994) 333-339
21. da Silva A.F., Desgranges P., Holdsworth J., Harris P.L., McCollum P., Jones S.M., et al. The management and outcome of critical limb ischaemia in diabetic patients: results of a national survey. Audit committee of the vascular surgical society of Great Britain and Ireland. Diabet Med 13 (1996) 726-728
22. da Silva A., Widmer L.K., Ziegler H.W., Nissen C., and Schweizer W. The Basle longitudinal study: report on the relation of initial glucose level to baseline ECG abnormalities, peripheral artery disease, and subsequent mortality. J Chronic Dis 32 (1979) 797-803
23. Vainio E., Salenius J.P., Lepantalo M., Luther M., and Ylonen K. Endovascular surgery for chronic limb ischaemia. Factors predicting immediate outcome on the basis of a nationwide vascular registry. Ann Chir Gynaecol 90 (2001) 86-91
24. Virkkunen J., Heikkinen M., Lepantalo M., Metsanoja R., and Salenius J.P. Diabetes as an independent risk factor for early postoperative complications in critical limb ischemia. J Vasc Surg 40 (2004) 761-767
25. AhChong A.K., Chiu K.M., Wong M.W., Hui H.K., and Yip A.W. Diabetes and the outcome of infrainguinal bypass for critical limb ischaemia. ANZ J Surg 74 (2004) 129-133
26. The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial. Am J Cardiol 75 (1995) 894-903
27. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
28. Dormandy J.A., Crarbonnel B., Eckland D.J.A., Erdmann E., Massi-Benedetti M., Moules I.K., et al. On behalf of the PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
29. De Backer G., Ambrosioni E., Borch-Johnsen K., Brotons C., Cifkova R., Dallongeville J., et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 24 (2003) 1601-1610
30. Kannel W.B. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol 76 (1995) 69C-77C
31. Smith I., Franks P.J., Greenhalgh R.M., Poulter N.R., and Powell J.T. The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischaemia. Eur J Vasc Endovasc Surg 11 (1996) 402-408 10.1053/ejvs.2001.1434
32. Cheng S.W., and Ting A.C. Lipoprotein (a) level and mortality in patients with critical lower limb ischaemia. Eur J Vasc Endovasc Surg 22 (2001) 124-129
33. Bismuth J., Kofoed S.C., Jensen A.S., Sethi A., and Sillesen H. Serum lipids act as inverse acute phase reactants and are falsely low in patients with critical limb ischemia. J Vasc Surg 36 (2002) 1005-1010
34. Buchwald H., Hunter D.W., Tuna N., Williams S.E., Boen J.R., Hansen B.J., et al. Myocardial infarction and percent arteriographic stenosis of culprit lesion: report from the Program on the Surgical Control of the Hyperlipidemias (POSCH). Atherosclerosis 138 (1998) 391-401
35. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21 (2001) 1712-1719
36. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4 S). Lancet 344 (1994) 1383-1389
37. Salonen R., Nyyssonen K., Porkkala E., Rummukainen J., Belder R., Park J.S., et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 92 (1995) 1758-1764
38. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
39. Schillinger M., Exner M., Mlekusch W., Amighi J., Sabeti S., Muellner M., et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J 25 (2004) 742-748
40. McDermott M.M., Guralnik J.M., Greenland P., Pearce W.H., Criqui M.H., Liu K., et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 107 (2003) 757-761
41. Mohler III E.R., Hiatt W.R., and Creager M.A. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108 (2003) 1481-1486
42. Henke P.K., Blackburn S., Proctor M.C., Stevens J., Mukherjee D., Rajagopalin S., et al. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. J Vasc Surg 39 (2004) 357-365
43. O'Neil-Callahan K., Katsimaglis G., Tepper M.R., Ryan J., Mosby C., Ioannidis J.P., et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) study. J Am Coll Cardiol 45 (2005) 336-342
44. Hirsch A.T., Criqui M.H., Treat-Jacobson D., Regensteiner J.G., Creager M.A., Olin J.W., et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286 (2001) 1317-1324
45. Meijer W.T., Grobbee D.E., Hunink M.G., Hofman A., and Hoes A.W. Determinants of peripheral arterial disease in the elderly: the Rotterdam study. Arch Intern Med 160 (2000) 2934-2938
46. Diehm C., Schuster A., Allenberg J.R., Darius H., Haberl R., Lange S., et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 172 (2004) 95-105
47. Hansson L., Zanchetti A., Carruthers S.G., Dahlof B., Elmfeldt D., Julius S., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351 (1998) 1755-1762
48. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 342 (2000) 145-153
49. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157 (1997) 2413-2446
50. Narins C.R., Zareba W., Moss A.J., Marder V.J., Ridker P.M., Krone R.J., et al. Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction. Arch Intern Med 164 (2004) 440-446
51. Radack K., and Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. a meta-analysis of randomized controlled trials. Arch Intern Med 151 (1991) 1769-1776
52. Heintzen M.P., and Strauer B.E. Peripheral vascular effects of beta-blockers. Eur Heart J 15 Suppl. C (1994) 2-7
53. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308 (1994) 81-106
54. Antiplatelet Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
55. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 308 (1994) 159-168
56. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996) 1329-1339
57. Clagett G.P., Sobel M., Jackson M.R., Lip G.Y., Tangelder M., and Verhaeghe R. Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 Suppl. 3 (2004) 609S-626S
58. Tran H., and Anand S.S. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 292 (2004) 1867-1874
59. The clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
60. Diener H.C., Bogousslavsky J., Brass L.M., Cimminiello C., Csiba L., Kaste M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 331-337
61. Willigendael E.M., Teijink J.A., Bartelink M.L., Kuiken B.W., Boiten J., Moll F.L., et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg 40 (2004) 1158-1165
62. Jonason T., and Ringqvist I. Factors of prognostic importance for subsequent rest pain in patients with intermittent claudication. Acta Med Scand 218 (1985) 27-33
63. Hirsch A.T., Treat-Jacobson D., Lando H.A., and Hatsukami D.K. The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. Vasc Med 2 (1997) 243-251
64. Ameli F.M., Stein M., Provan J.L., and Prosser L. The effects of postoperative smoking on femoropopliteal bypass grafts. Ann Vasc Surg 3 (1989) 20-25
65. Quick C.R., and Cotton L.T. The measured effect of stopping smoking on intermittent claudication. Br J Surg 69 Suppl. (1982) S24-S26
66. Jonason T., and Bergström R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand 221 (1987) 253-260
67. Rosenberg L., Palmer J.R., and Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med 322 (1990) 214-217
68. Ingolfsson I.O., Sigurdsson G., Sigvaldason H., Thorgeirsson G., and Sigfusson N. A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968-1986: a strong relationship to smoking and serum cholesterol-the Reykjavik Study. J Clin Epidemiol 47 (1994) 1237-1243
69. Silagy C., Lancaster T., Stead L., Mant D., and Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev Issue 3 (2004) 10.1002/14651858.CD000146 pub2. Art. No.: CD000146.
70. Dale L.C., Glover E.D., Sachs D.P., Schroeder D.R., Offord K.P., Croghan I.T., et al. Bupropion for smoking cessation: predictors of successful outcome. Chest 119 (2001) 1357-1364
71. Mukherjee D., Lingam P., Chetcuti S., Grossman P.M., Moscucci M., Luciano A.E., et al. Missed opportunities to treat atherosclerosis in patients undergoing peripheral vascular interventions: insights from the University of Michigan Peripheral Vascular Disease Quality Improvement Initiative (PVD-QI2). Circulation 106 (2002) 1909-1912
72. Ness J., Aronow W.S., Newkirk E., and McDanel D. Prevalence of symptomatic peripheral arterial disease, modifiable risk factors, and appropriate use of drugs in the treatment of peripheral arterial disease in older persons seen in a university general medicine clinic. J Gerontol A Biol Sci Med Sci 60 (2005) 255-257
73. Bismuth J., Klitfod L., and Sillesen H. The lack of cardiovascular risk factor management in patients with critical limb ischaemia. Eur J Vasc Endovasc Surg 21 (2001) 143-146 10.1053/ejvs.2000.1293
74. Barani J., Mattiasson I., Lindblad B., and Gottsäter A. Suboptimal treatment of risk factor for athero-sclerosis in critical limb ischemia. Int Angiol 24 (2005) 59-63